Abstract:Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by T cell overactivation and B cell hyper-stimulation. Hematopoietic progenitor kinase 1 (HPK1, also called MAP4K1) negatively regulates T cell-mediated immune responses. However, the role of HPK1 and the mechanisms that regulate HPK1 expression in SLE remain poorly understood. Using chromatin immunoprecipitation (ChIP) microarray data, we identified markedly increased histone H3 lysine 27 trimethylation (H3K27me3) enrichment at the HPK1 promoter of SLE CD4+ T cells relative to controls, and confirmed this observation using ChIP and real-time PCR experiments. We further found that HPK1 mRNA and protein levels were significantly decreased in CD4+ T cells of patients with SLE, and that this decrease was not caused by exposure to standard SLE medications. Down-regulating HPK1 in healthy CD4+ T cells significantly accelerated T cell proliferation and production of IFNγ and IgG. Consistent with these findings, overexpressing HPK1 in SLE CD4+ T cells caused a significant decrease in T cell reactivity. In addition, we observed a striking decrease in jumonji domain containing 3 (JMJD3) binding, but no marked change in enhancer of zeste homolog 2 (EZH2) binding, at the HPK1 promoter region in SLE CD4+ T cells compared to healthy controls. SiRNA knock down of JMJD3 in healthy CD4+ T cells led to decreased JMJD3 binding and increased H3K27me3 enrichment at the HPK1 promoter region, thus inhibiting the expression of HPK1. Concordantly, plasmid-induced overexpression of JMJD3 in SLE CD4+ T cells led to increased JMJD3 binding, decreased H3K27me3 enrichment, and up-regulated HPK1 expression. Our results show for the first time that inhibited HPK1 expression in SLE CD4+ T cells is associated with loss of JMJD3 binding and increased H3K27me3 enrichment at the HPK1 promoter, contributing to T cell overactivation and B cell overstimulation in SLE. These findings suggest that HPK1 may serve as a novel target for effective SLE therapy.

Aberrant expression of JMJD3 in SLE promotes B-cell differentiation.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus.

JMJD3 participates in activation and apoptosis of IFN-αand TLR7-induced B cells

Abnormal Expression of Cd43 in Patients with Systemic Lupus Erythematosus and Its Clinical Significance

Decreased Jumonji Domain-Containing 3 at the Promoter Downregulates Hematopoietic Progenitor Kinase 1 Expression and Cytoactivity of T Follicular Helper Cells from Systemic Lupus Erythematosus Patients

JMJD3 Facilitates C/EBPβ-centered Transcriptional Program to Exert Oncorepressor Activity in AML

B cell function in patients with systemic lupus erythematosus is regulated by the upregulation of JunD

Aberrant H3K4me3 modification of immune response genes in CD4 + T cells of patients with systemic lupus erythematosus

Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus

BCL-6 suppresses miR-142-3p/5p expression in SLE CD4<SUP>+</SUP> T cells by modulating histone methylation and acetylation of the miR-142 promoter

BCL-6 suppresses miR-142-3p/5p expression in SLE CD4 + T cells by modulating histone methylation and acetylation of the miR-142 promoter

Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus.

Epigenetic programming underpins B cell dysfunction in human SLE

The Influence of GATA3 and MBD2 on the Expression of IL-4 in SLE

UHRF1 downregulation promotes T follicular helper cell differentiation by increasing BCL6 expression in SLE

Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis

Myeloid-derived suppressor cells contribute to systemic lupus erythematosus by regulating differentiation of Th17 cells and Treg.

Dysregulation of type I IFN and IL-4R signaling regulates the development of BCR VH and VL repertoire encoding anti-Sm autoantibodies in SLE

Down-regulation of MBD4 contributes to hypomethylation and overexpression of CD70 in CD4 + T cells in systemic lupus erythematosus